Jane Street Group LLC Sells 53,404 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Jane Street Group LLC lessened its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 67.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 25,256 shares of the company’s stock after selling 53,404 shares during the period. Jane Street Group LLC’s holdings in Perspective Therapeutics were worth $337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in Perspective Therapeutics by 214.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after purchasing an additional 93,548 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Perspective Therapeutics during the second quarter valued at about $630,000. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the second quarter worth about $117,000. ClariVest Asset Management LLC bought a new position in Perspective Therapeutics during the second quarter valued at about $540,000. Finally, Sykon Capital LLC raised its holdings in Perspective Therapeutics by 4.7% in the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after acquiring an additional 1,717 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CATX shares. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research report on Monday, November 25th. Royal Bank of Canada lowered their price target on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a report on Monday, November 25th. Oppenheimer reduced their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, UBS Group assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.14.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 14,500 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the business’s stock in a transaction on Monday, November 25th. The shares were acquired at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the transaction, the chief financial officer now owns 48,800 shares in the company, valued at approximately $186,416. This trade represents a 35.66 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 67,570 shares of company stock worth $256,789. Insiders own 3.52% of the company’s stock.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $3.53 on Friday. The company’s 50-day moving average price is $5.33 and its two-hundred day moving average price is $10.28. Perspective Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million for the quarter. As a group, analysts forecast that Perspective Therapeutics, Inc. will post -0.88 EPS for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.